Search Results

You are looking at 1 - 8 of 8 items for :

  • "levetiracetam" x
  • All content x
Clear All

Levetiracetam (LT) is an FDA-approved orally active anticonvulsant drug. A high-performance thin-layer chromatographic (HPTLC) method for the analysis of LT in a tablet formulation has been developed and validated. Separation is performed on silica gel 60 F254 with toluene-ethyl acetate-methanol, 2:1:1 (v/v/v) as mobile phase. Densitometric evaluation of the separated zone is carried out at 204 nm. There is no chromatographic interference from the tablet excipients, and compact spots are observed for LT (R F = 0.50 ± 0.02). Regressional analysis of the calibration plot revealed good linearity over the concentration range of 0.1–1.0 μg/mL. The method is validated for linearity, precision, robustness, and recovery in accordance with ICH guidelines. The LOD and LOQ were found to be 0.03 and 0.1 μg/spot, respectively. Stability was checked under acidic, alkaline, and aquatic environmental stress conditions. The drug was found to be more than 65% undegraded after 14 days of study. The developed method might be useful in the quality control of LT in the pharmaceutical industry and environmental toxicity assessments.

Restricted access
Orvosi Hetilap
Authors: József Janszky, Beáta Bóné, Réka Horváth, Zsófia Sütő, László Szapáry, Vera Juhos, Sámuel Komoly, and Norbert Kovács

Absztrakt:

A status epilepticus a második leggyakoribb, sürgősségi kezelést igénylő neurológiai állapot. Halálozása 15–25%. A „time is brain” elve a status epilepticus kezelésére is igaz: minél korábban kezdjük a megfelelő kezelést, annál nagyobb valószínűséggel tudjuk megállítani a progressziót. Magas szintű evidenciákon alapuló kezelési protokollal a status epilepticus progressziója az esetek 75–90%-ában megelőzhető, az indukált kóma és a halálos kimenetel elkerülhető. A status epilepticus kezelése akkor a legsikeresebb, ha már a korai szakban megkezdjük a parenteralis benzodiazepinterápiát: im. midazolám (0,2 mg/tskg, max. 10 mg). Szabad véna esetén lehet vénásan is adni a benzodiazepint (10 mg diazepám iv). Ha az első benzodiazepinbolusra nem reagál a status epilepticus, állandósult (benzodiazepinrefrakter) status epilepticusról beszélünk. Ilyenkor a benzodiazepin ismétlésével párhuzamosan nem benzodiazepin típusú, gyorsan ható vénás antiepileptikumot is adni kell: iv. valproát (40 mg/kg, max. 3000 mg, 10 perc alatt) vagy levetiracetám (60 mg/kg, max. 4500 mg, 10 perc alatt) javasolt. Az 1 órán túl is tartó, sem benzodiazepinre, sem antiepileptikumra nem reagáló, refrakter status epilepticust neurointenzív osztályon, teljes narcosissal (indukált kómával) kell kezelni. Az indukált kómát gyors hatású anesztetikummal lehet elérni, elsősorban propofol–midazolám kombinációval. Orv Hetil. 2020; 161(42): 1779–1786.

Open access

A quantitative densitometric high-performance thin-layer chromatographic (HPTLC) method has been established for analysis for two anti epileptic drugs, levetiracetam and oxcarbazepine in tablets. Separations on silica gel 60 F 254 HPTLC plates with toluene-acetone-methanol, 6:2:2 ( v/v ), as mobile phase enabled satisfactory resolution of the two drugs. This system afforded well resolved compact bands for levetiracetam and oxcarbazepine at R F 0.45 ± 0.02 and 0.55 ± 0.02, respectively. Densitometric scanning was performed in absorbance/reflectance mode at 200 and 261 nm. The method was successfully validated for precision, robustness, ruggedness, and recovery. The drugs were also subjected to photodegradation studies; oxcarbazepine was degraded in 9 h and levetiracetam was not degraded even after a long period. The method was found to be accurate and compatible with the conditions used.

Restricted access

–1273. 29 Grünewald, R.: Levetiracetam in the treatment of idiopathic generalized epilepsies. Epilepsia, 2005, 46 (Suppl. 9), 154–160. 30 Patsalos, P

Restricted access
Orvosi Hetilap
Authors: Zsuzsanna Kemény, Patrícia Pálfi, Judit Demeter, Gyula Poór, Emese Kiss, and Péter Bálint

Sechi, G. P., Barrocu, M., Piluzza, M. G.: Levetiracetam in stiff-person syndrome. J. Neurol., 2008, 255 , 1721–1725. Piluzza M. G. Levetiracetam in stiff-person syndrome

Open access
Biologia Futura
Authors: Esra Aciman Demirel, Mumin Alper Erdoğan, Bilge Piri Cinar, and Oytun Erbas

antiepileptics are also available, including levetiracetam, topiramate, zonisamide, and lacosamide. However, in addition to the effectiveness of these options, they are also capable of producing various metabolic, psychiatric, and behavioral side effects

Restricted access

referred for evaluation due to epileptic seizures twice per month and an intermittent body tremor. Levetiracetam (20 mg/kg) BID and carbamazepine (2 mg/kg BID) were started 7 months before referral. Neurological examination did not show any abnormalities

Open access
European Journal of Microbiology and Immunology
Authors: Markus Krohn, Thomas Wanek, Marie-Claude Menet, Andreas Noack, Xavier Declèves, Oliver Langer, Wolfgang Löscher, and Jens Pahnke

Fedrowitz , M Potschka , H Kaever , V Löscher , W . Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine

Open access